If Bio-Reference does not disappoint with the consensus estimate at 43 cents and surprises at 45 cents or more, the stock should make a new high in the next few market sessions. This looks like the year that will demonstrate the value of the company capital investment in cancer genetics and other esoteric units of Bio-Reference's GenPath division.
This news story has 1 comment: